Press releases

PEPperPRINT and Sciomics announce Partnership Agreement

 

Heidelberg, 18th November, 2014

 

Sciomics and PEPperPRINT agreed on a partnership for the co-distribution and co-marketing of their product and service portfolios with the aim to provide a comprehensive microarray toolbox for antibody characterization and biomarker discovery.

 

A joint two-step process for antibody characterization will enable the selection of the optimal antibody from a set of antibody candidates for therapeutic, diagnostic or research purposes. Sciomics will offer its custom antibody microarray platform as well as protein arrays for target binding validation and cross-reactivity analysis. Selected candidates will be further characterized by epitope mapping and epitope substitution scans provided by PEPperPRINT to identify conserved and variable amino acids as well as possible cross-reactions from a bioinformatics analysis of conserved core motifs.

 

The combination of peptide and antibody microarrays by PEPperPRINT and Sciomics further provides a powerful approach for discovery, in-depth characterization and validation of new serum biomarkers including antibodies and serum proteins. A combination of the core strengths of the respective platforms enables a robust and cost-efficient discovery of protein as well as autoantibody biomarker candidates in a highly multiplexed fashion. This increases the likelihood of identifying the optimal biomarker candidates and furthermore can increase the assay accuracy by combining information derived from both platforms.

 

“The partnership agreement is based on a long lasting research relationship and highest appreciation of Sciomics scientific competences. A combination of the core technologies of both companies allows customers to benefit from our complementary and powerful microarray tool box” says Dr. Volker Stadler, CEO of PEPperPRINT. “The fact that both companies are located in Heidelberg certainly facilitates logistics and scientific collaboration and underlines the strength of the Heidelberg biotech cluster.”

 

"Sciomics is very glad to have entered into a partnership with PEPperPRINT. This complements our own expertise and portfolio in antibody characterization with the strong expertise of the PEPperPRINT team." says Dr. Christoph Schröder, CEO of Sciomics. "For biomarker research, combining the powerful microarray platforms of PEPperPRINT and Sciomics enables a most comprehensive coverage of all topics concerning discovery, verification as well as in-depth characterization of biomarker candidates. This partnership enables us to provide the maximum amount of value to our customer's projects."

 

Click here for Press Release as pdf-file.

 

 

 

 

PEPperPRINT
Dr. Lisa Steinbrück
Head of Business Development
Rischerstr. 12
D-69123 Heidelberg
Germany

Phone: +49 (0)6221 72644-89
Fax : +49 (0)6221 72644-75
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Web: www.pepperprint.com

Sciomics GmbH
Dr. Ronny Schmidt
Business Development
Schneidmühlstr. 19
D-69115 Heidelberg
Germany

Phone: +49 (0) 6221 3283140
Fax : +49 (0) 6221 4294834
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Web: http://www.sciomics.de

News

Article | Parkinson’s Striatum Organoids Show Increased Inflammation Hallmarks

| February 2026 | Patient-derived striatum organoids carrying the LRRK2-G2019S mutation reveal early Parkinson’s Disease features, including neuroinflammation and altered signalling. Sciomics supported the study by analysing patient-derived striatum organoids using the scioDiscover proteomic microarray.

Barmpa et al., Parkinson’s Disease Patient-Specific Striatum Organoids Show Hallmarks of Increased Inflammation. Mov Disord. (2026), published online February 11, 2026  
Article | Fos-induced Osteosarcoma Links Cachexia-like Wasting to FGF21

| February 2026 | Fos-driven osteosarcoma induces systemic metabolic alterations and identified FGF21 as a key mediator and promising biomarker of cancer-associated cachexia. Sciomics supported the study by analysing murine serum samples using the scioDiscover proteomic microarray.

Luther et al., Fos-induced osteosarcoma growth causes a cachexia-like phenotype in mice and correlates with high Fgf21 serum levels. Cancer Metab. (2026)  
Article | Transpulmonary Pressure-Guided PEEP Improves Lung Protection

| October 2025 | In a porcine lung injury model, transpulmonary pressure–guided PEEP titration improved mechanics and reduced tidal stress. Sciomics supported the study by analysing cytokine, chemokine, and surface marker expression levels in plasma samples using the scioCD Precision Proteomics platform.

Mutschler et al., Optimizing Positive End-Expiratory Pressure in Asymmetric Acute Lung Injury in a Porcine Model: The Role of Transpulmonary Pressure. Int. J. Mol. Sci. 2025, 26, 9985  
Article | Long-Term Biobanked Dental Pulp Stem Cells Retain Angiogenic Potential

| September 2025 | Biobanked dental pulp stem cells preserved for years retained their angiogenic capacity and stem cell phenotype. Sciomics supported the study by analysing cell differentiation marker profiles from dental pulp stem cells using the scioCD Precision Proteomics platform.

Yamada et al., Long-Term Biobanked Dental Pulp Stem Cells Retain Angiogenic Potential for Vascularised Tissue Engineering—Laboratory Investigation. Int. Endod. J. (2025, online ahead of print)
Article | Fibroblast–monocyte signalling via TLR4 drives TNBC metastasis

| September 2025 | A TLR4-dependent axis between fibroblasts and monocytes in tumor-draining lymph nodes drives metastasis in triple-negative breast cancer. Sciomics provided protein profiling of lymph node and tumor samples to map surface- and immune-related protein changes using the scioCD protein profiling platform.

Mattavelli et al., A TLR4-dependent fibroblast-monocyte axis in tumor-draining lymph nodes contributes to metastasis in triple-negative breast cancer. Immunity. 2025 Sep 15 (online ahead of print)  

Meet us

BIO 2026—San Diego (June 22-25, 2026)

We are excited to be part of BIO International Convention (June 22-25 in San Diego). Meet our CEO Dr. Christoph Schröder at the German Pavilion.
Swiss Biotech Day 2026—Basel (May 04-05, 2026)

Meet Dr. Ronny Schmidt, our VP Contract Research on-site at Swiss Biotech Day (May 04-05 in Basel).
bioRN Lounge (every last Tuesday of the month)

Want to meet in person? Talk to us at the bioRN Lounge, the regional monthly networking event in Heidelberg taking place every last Tuesday of the month.

Testimonials

PD Dr. med. Mascha O. Fiedler-Kalenka and Dr. med. Benjamin Seybold

Heidelberg University Hospital, Department of Anesthesiology, Heidelberg, GermanyGerman Center for Lung Research (DZL), Translational Lung Research Center Heidelberg (TLRC), Heidelberg, Germany

"From the very beginning, working with the friendly and highly competent team at Sciomics was both professional and refreshingly straightforward. We particularly valued their openness to our specific research questions and the expert support they provided in planning and interpreting our exploratory cytokine analysis in a preclinical lung injury model. Communication was always on equal footing, enriched by Sciomics’ deep expertise, which also sparked new ideas for future projects."

Product: scioCD

Tara Sigdel, PhD

Associate Professor, Department of Surgery, University of California San Francisco

"We collaborated with Sciomics GmbH in Germany to analyze proteomics data from blood samples of kidney transplant recipients and liver perfusates during normothermic machine perfusion. Throughout the process, Sciomics provided exceptional support, ensuring timely data delivery and valuable assistance with data analysis. Their expertise and commitment have been instrumental in advancing our research, and we are currently using their data in multiple manuscript submissions. I highly recommend Sciomics for their reliable service and expertise in proteomics."

Product: scioDiscover

BACK_TO_TOP